NOVAVAX INC Common Stock, Value, Issued
NOVAVAX INC (NVAX) had Common Stock, Value, Issued of $1.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-06
- 2026-06-30: Common Stock, Value, Issued $1.68M.
- 2026-03-31: Common Stock, Value, Issued $1.68M.
- 2025-12-31: Common Stock, Value, Issued $1.65M.
- 2025-09-30: Common Stock, Value, Issued $1.65M.
| Period end | Common Stock, Value, Issued | Common Stock, Value, Issued as first filed |
|---|---|---|
| 2026-06-30 | $1.68M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.68M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.65M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.65M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.65M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $1.64M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.62M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.62M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.61M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.42M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $1.41M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.20M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $952.00K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $871.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $868.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | $792.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $788.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $787.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $764.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | $760.00K 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $747.00K 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $745.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $714.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $633.00K 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $612.00K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $539.00K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $324.00K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $256.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $235.00K 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $4.70M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $192.00K 10-K · filed 2020-03-11 | $3.85M 10-K · filed 2019-03-18 |
| 2018-09-30 | $3.83M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $3.82M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $3.47M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.24M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $3.11M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $2.90M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $2.83M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $2.72M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $2.72M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $2.71M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $2.71M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $2.70M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $2.70M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $2.69M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $2.68M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $2.39M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $2.39M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $2.39M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $2.10M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $2.09M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $2.09M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $1.53M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | $1.52M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $1.48M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $1.36M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $1.33M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $1.23M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $1.18M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $1.15M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $1.15M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $1.11M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |